Genmab A/S (GNMSF)
| Previous close | 281.02 |
| Open | 281.08 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 279.82 - 290.38 |
| 52-week range | 262.00 - 426.50 |
| Volume | |
| Avg. volume | 983 |
| Market cap | 18.873B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 30.86 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investor's Business Daily
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.
- Insider Monkey
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
- Insider Monkey
Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript
Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript February 14, 2024 Genmab A/S misses on earnings expectations. Reported EPS is $0.14 EPS, expectations were $0.35. Genmab A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you […]
